ACHE and myasthenia gravis: During the RCP of the study, 85 patients (99%) who were administered ravulizumab received concomitant MG medications: 72 (84%) received acetylcholinesterase inhibitors, 57 (66%) received systemic corticosteroids, and 56 (65%) received non-steroidal immunosuppressants.